Related coverage linked through entity extraction aliases.
Apr 19, 2026
Studies on immune checkpoint inhibitor therapy found pretreatment biomarkers strongly predicted checkpoint inhibitor-associated autoimmune diabetes, while hyperglycemia during treatment was common and did not worsen disease progression.
Mar 01, 2026
Phase 2 SWOG S1512 trial shows neoadjuvant pembrolizumab achieved 71% pathologic complete response in resectable desmoplastic melanoma with 3-year survival rates of 74% for relapse-free and 87% for overall survival.
Feb 14, 2026
Immatics received FDA orphan drug designation for its melanoma therapy targeting Stage II and higher cutaneous melanoma in HLA-A 02:01-positive patients, marking a regulatory milestone that brings potential market exclusivity benefits.
